Joseph Monahan - Sep 1, 2021 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Scientific Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Sep 1, 2021
Transactions value $
-$17,926
Form type
4
Date filed
9/2/2021, 05:39 PM
Previous filing
Jun 2, 2021
Next filing
Feb 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +2.33K +2.73% 87.7K Sep 1, 2021 Direct F1
transaction ACRS Common Stock Tax liability -$17.9K -1.04K -1.19% $17.22 86.6K Sep 1, 2021 Direct F2
holding ACRS Common Stock 193 Sep 1, 2021 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -2.33K -100% $0.00* 0 Sep 1, 2021 Common Stock 2.33K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3 The shares underlying these restricted stock units vested on September 1, 2021.